Mostrar el registro sencillo del ítem

dc.contributor.authorAntolin, A. Rodriguez
dc.contributor.authorMartinez-Pineiro, L.
dc.contributor.authorRomero, M. E. Jimenez
dc.contributor.authorRamos, J. B. Garcia
dc.contributor.authorLópez Bellido, Dionisio 
dc.contributor.authordel Toro, J. Munoz
dc.contributor.authorGarcia-Porrero, A. Garcia
dc.contributor.authorVeiga, F. Gomez
dc.date.accessioned2022-02-02T08:15:47Z
dc.date.available2022-02-02T08:15:47Z
dc.date.issued2019
dc.identifier.issn1471-2490
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796370/pdf/12894_2019_Article_527.pdfes
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16065
dc.description.abstractBACKGROUND: Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of fatigue and its impact on quality of life (QoL) in patients with CRPC in routine clinical practice. METHODS: This was a cross-sectional, multicentre study. Male chemo-naive adults with high-risk non-metastatic (M0) CRPC and metastatic (M1) CRPC (mCRPC) were eligible. Fatigue was measured using the Brief Fatigue Inventory (BFI) and QoL was assessed using the Functional Assessment of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) questionnaire. Data were analysed using Mann-Whitney or Kruskal-Wallis tests (non-parametric distribution), a T-test or an ANOVA (parametric distribution) and the Fisher or chi-squared tests (categorical variables). RESULTS: A total of 235 eligible patients were included in the study (74 [31.5%] with M0; and 161 [68.5%] with M1). Fatigue was present in 74%, with 38.5% of patients reporting moderate-to-severe fatigue. Mean FACT-G and FACT-P overall scores were 77.6 +/- 16.3 and 108.7 +/- 21.4, respectively, with no differences between the CRPC M0 and CRPC M1 subgroups. Fatigue intensity was associated with decreased FACT-G/P scores, with no differences between groups. Among 151 mCRPC patients with available treatment data, those treated with abiraterone-prednisone >/=3 months showed a significant reduction in fatigue intensity (p = 0.043) and interference (p = 0.04) compared to those on traditional hormone therapy (HT). Patients on abiraterone-prednisone >/=3 months showed significantly better FACT-G/P scores than patients on HT (p = 0.046 and 0.018, respectively). CONCLUSION: Our data show a high prevalence and intensity of fatigue and its impact on QoL in chemo-naive CRPC patients. There is an association between greater fatigue and less QoL, irrespective of the presence or absence of metastasis. Chemo-naive mCRPC patients receiving more than 3 months of abiraterone acetate plus prednisone showed an improvement of fatigue and QoL when compared to those on traditional HT. TRIAL REGISTRATION: Not applicable since it is not an interventional study.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshMiddle Aged*
dc.subject.meshHumans*
dc.subject.meshCross-Sectional Studies*
dc.subject.meshProstatic Neoplasms*
dc.subject.meshFatigue*
dc.subject.meshQuality of Life*
dc.subject.meshAged*
dc.subject.meshPrevalence*
dc.titlePrevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL studyen
dc.typeArtigoes
dc.identifier.doi10.1186/s12894-019-0527-8
dc.identifier.pmid31619215
dc.identifier.sophos34150
dc.issue.number1es
dc.journal.titleBmc urologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Uroloxíaes
dc.page.initial92es
dc.rights.accessRightsopenAccesses
dc.subject.decsanciano*
dc.subject.decsneoplasias de la próstata*
dc.subject.decsprevalencia*
dc.subject.decsmediana edad*
dc.subject.decshumanos*
dc.subject.decsfatiga*
dc.subject.decsestudios transversales*
dc.subject.decscalidad de vida*
dc.subject.keywordCHUOes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number19es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional